Inhibikase Therapeutics (IKT) Reports First Patients Dosed in Phase 1 Clinical Trial of IkT-148009 to Treat Parkinson’s Disease and Related Disorders

February 17, 2021 8:10 AM EST

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Inhibikase Therapeutics, Inc. (NASDAQ: IKT) today announced dosing of the first patients in its Phase 1 clinical trial of IkT-148009, an Abelson Tyrosine Kinase, or c-Abl, inhibitor for the treatment of Parkinson’s disease.

This randomized Phase 1 study is investigating the safety, tolerability and pharmacokinetics (PK) of IkT-148009 in healthy volunteers aged 45 to 70 years old with the objective of identifying the maximum tolerated dose and the PK profile of IkT-148009 in single and multiple ascending dose settings. In preclinical animal models of progressive disease, the Company demonstrated that once a day oral therapy with IkT-148009 can both halt and reverse functional loss in the brain and gastrointestinal tract.

“The initiation of our Phase 1 study of IkT-148009 for the treatment of Parkinson’s disease represents a significant milestone for Inhibikase. Based on preclinical data, we believe that c-Abl plays a critical role in the Parkinson’s disease process and inhibition of c-Abl represents a promising new approach to disease modification,” stated Milton Werner, Ph.D., Chief Executive Officer of Inhibikase Therapeutics. “We are excited to advance into the clinic, and believe that IKT-148009 could be a transformative therapy for millions of patients worldwide.”

Activation of c-Abl, in humans occurs once plaques of alpha-synuclein are internalized by the affected neurons. C-Abl then drives biochemical pathways and processes that lead to degradation of the neurons affected in Parkinson’s disease. Inhibition of c-Abl may restore functional loss for neurons that have not fully degraded in the brain and remodel neurons in the gastrointestinal tract, two major organ systems affected by the disease.

About Parkinson’s Disease

Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder, affecting approximately 1,000,000 persons in the United States, with 60,000 new cases and 38,000 deaths annually. PD is a progressive neurodegenerative disease that initiates with dysfunction of a small protein known as alpha-synuclein, inside and outside of the brain. The common features of PD include tremors at a resting state, slowing or lack of control of movement and postural instability. These features of the disease arise from degeneration of neurons that secrete dopamine to transmit neurological signals. The degeneration of these dopaminergic neurons in nigrostriatal area of the brain near the brainstem, coupled with the accumulation of alpha-synuclein protein aggregates in cell bodies and terminals known as Lewy bodies, have long been thought to be the cause of the disease. Less well known are the features of this disease can affect serotonin levels, cholinergic, and norepinephrine neurons and nerve cells in the olfactory system, cerebral hemisphere, brain stem, spinal cord, and peripheral autonomic nervous system such as in the GI tract. Currently, these non-dopaminergic features are not properly controlled with dopamine-replacement or levodopa therapy.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA, Management Comments

Related Entities